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price in high-risk patients?Lars G. Svensson, MD, PhDThe use of methods for insertion of percutaneous valves has
increased more rapidly than anticipated, particularly in view
of the fact that there were early problems with both clinical
and animal research.1-7 Indeed, preliminary trials with the
transapically inserted aortic valves were associated with
a high risk of embolization.4 There were 3 likely reasons
for this. (1) There was no calcification in the aortic valve
to anchor the stent, (2) the juvenile animals had a pliable
annulus, and (3) some of the earlier devices were covered
with a smooth cloth. Furthermore, the transfemoral venous
approach pioneered by Cribier and colleagues1 was associ-
ated with problems related to the complexity of the trans-
septal approach, which also required making the device
snake through the left ventricle, resulting in both a high in-
cidence of stroke and death. Nevertheless, the perseverance
of Webb and associates2 resulted in the development of the
retrograde transfemoral aortic approach, which has become
the method of choice whereby 50% to two thirds of devices
are inserted. At the same time, CoreValve,5,6 now owned by
Medtronic (Minneapolis, Minn), developed a retrograde
transfemoral approach that has also resulted in many
devices being inserted. In total, some 15,000 devices have
now been inserted in patients around the world.
For a valve procedure to be accepted into practice, 4 criteria
are required: (1) Insertion is easy, (2) the procedure is safe, (3)
the result has an acceptable effective orifice area, and (4) the
long-term durability and survival is good. Research continues
on whether the new percutaneous valves meet these criteria.
For the transapical approach, an anterior–lateral thoracot-
omy ismade in the fifth or sixth intercostal spacewith orwith-
out a rib resection (Figure 1). Purse-string sutures are then
placed in the left ventricular apex. At the same time, a transfe-
moral venous pacing wire is inserted, and a transarterial pig-
tail fed up into the aortic root. Next, a needle followed by
a short guide wire is inserted in the left ventricle: The needle
is removed, a size 14 sheath is inserted, the wire is removed,
and a Berman balloon catheter under fluoroscopy is fed intoFrom the Aorta Center, Marfan and CTD Clinic, the Cleveland Clinic, Cleveland,
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S10 The Journal of Thoracic and Cardiovascular Surgthe left ventricle, and then across the aortic valve down to
the renal arteries, using fluoroscopy for positioning. The extra
stiff wire is fed through the Berman catheter down to the renal
arteries (if it has not already been used for crossing the aortic
arch). In some patients, the difficulty of negotiating the aortic
arch may require the use of a Wooley wire to maneuver
around the arch. At this stage, both the Berman balloon cath-
eter and the 14F sheath are removed, and the large-bore deliv-
ery introducer sheath is inserted into the left ventricular apex,
enabling the dilator to be removed. A 3- to 5-cm balloon is
then fed over the wire into the native aortic valve and, during
rapid pacing, inflated to perform the valvuloplasty. Now,
transesophageal echocardiography is used to check the result.
The new stent valve is then mounted on a balloon in a loader,
and the loader is connected to the end of the sheath and used
for feeding the newdevice into the apex of the ventricle.Next,
the device is pushed across the native valve and the pusher
catheter is drawn back into the large-bore delivery sheath. Af-
ter careful positioning of the valve using transesophageal
echocardiography, flushing of the aortic root with contrast
dye, and noting the positioning of the valve in relation to
calcium in the root, rapid pacing is commenced (usually at
180 beats/min) and the patient’s breath held. The valve is
deployed by inflating the balloon. More recently, we have
been deploying and inflating the balloon at a slower pace,
which allows us to reposition the valve if there has been
movement during the period of inflation. Thus, the valve
can be positioned more ‘‘aortic’’ or ‘‘ventricular’’ during
deployment to adjust for movement. Then, the balloon is
then withdrawn into the sheath and positioning checked by
transesophageal echo and fluoroscopy.
For the first 40 very high-risk patients undergoing this
procedure in the United States during the feasibility trial,
the mortality rate was 17%,3 but in those patients who had
a successful operation and insertion of the device, the effec-
tive orifice areas and reduction in gradients were impressive.
No strokes occurred immediately after the procedure in pa-
tients who had a successful valve deployment.
The transfemoral retrograde arterial approach involves
placing a transvenouswire for pacing and insertion of a trans-
femoral pigtail and then a large-bore sheath into the other
femoral artery (Figure 2). The subsequent procedure of bal-
loon valvuloplasty, followed by inflation of the balloon with
the stent device, is similar to the transapical approach. In
most patients, a femoral artery or vein cut-down is not
needed. In the United States, the transfemoral aortic valve
insertion feasibility trial ([Percutaneous Endovascularery c December 2010
FIGURE 1. Steps in the insertion of a transapical aortic valve. A, Purse sting and transducer positioning. B, Apogeefig_2 Sheath and device insertion. C,
Stent deployment, first balloon valvuloplasty, positioning device, and balloon inflation.
Svensson Aortic Symposium 2010Implantation of Valves trial [REVIVAL]) results showed the
risk of death was 7%, the risk of stroke was 9%, and the risk
of vascular injury was 13%.
After the feasibility trials, the Placement of Aortic Trans-
catheter Valves (PARTNER) randomized trial was com-
menced. In this study, the patients were randomized to
group A (high-risk surgical, N ¼ 700) or B (inoperable,
N¼ 358).GroupApatientswere randomized to open surgery
or device, inserted by the transfemoral approach if good ac-
cess was present, or the transapical approach if femoral arteryThe Journal of Thoracic and Caraccess was not possible. Group B patients were randomized
to transfemoral insertion or best medical treatment. The entry
criteria were strict, with all patients required to have a valve
area less than 0.8 cm2 and, for group A, a Society of Thoracic
Surgeons’ score greater than 10%. Eighty-seven percent of
those receiving ‘‘best medical treatment’’ underwent valvu-
loplasty. Group B enrollment was completed by March 16,
2009, and group A enrollment was completed by August
28, 2009. The results of group B were reported September
28, 2010, and the results of group A are expected in Marchdiovascular Surgery c Volume 140, Number 6S S11
FIGURE 2. Steps in the insertion of a transfemoral arterial aortic valve. A, Flexible catheter introduction. B, Flexing catheter around the arch. C, Device
deployment, first balloon valvuloplasty, device placement, balloon inflation with device, positioned new valve.
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a 6.4% 30-day procedure mortality and 5% major stroke
rate but at 2 years the survival was 67% better (P< .0001).
Meanwhile, continued access is allowed. PARTNER IIB
commences later this year, and group A likely commences
thereafter. The entry criteria will be somewhat modified,
and access will be with a new smaller 18F device.
The CoreValve device (depending on Food and Drug Ad-
ministration approval) will probably be inserted in patientsS12 The Journal of Thoracic and Cardiovascular Surgin the United States in 2010 or 2011. A number of test sites
have been approved by the sponsor, Medtronic. The sites
include the primary investigator sites of Mt Sinai in New
York and Beth Israel Deaconess in Boston.
CONCLUSIONS
Transapical and transarterial valve insertion approaches
have become viable treatment options in high-risk and
inoperable patients. Clearly, PARTNER B has shownery c December 2010
Svensson Aortic Symposium 2010significant improvement over medical treatment in inoper-
able patients but at the price of stroke. The PARTNER A
trial outcomes will be watched with great interest because
this is a comparison with surgery. The progress of trials
using the CoreValve device has just been approved.
Thus, although these new devices are easy to insert, safe
in inoperable patients, and with equivalent hemodynamics
to open valve replacement, the long-term durability is un-
known and the price of insertion needs to be reduced.References
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